Latham Advises ATAI Life Sciences on US$125 Million Series C

London and Frankfurt teams act for biotechnology company in financing round.

November 27, 2020

Latham & Watkins advised ATAI Life Sciences, a global biotech platform, in raising US$125 million in a Series C financing round.

The financing was led by Apeiron Investment Group, Peter Thiel and Catalio Capital Management.

Proceeds from the financing will be used primarily to fund pre-clinical and clinical development of ATAI's existing mental health programs, to expand its drug candidate pipeline and further advance ATAI's platform technologies.

The Latham team was led by London corporate partner Robbie McLaren and Frankfurt corporate partner Markus Krueger, with associates Jon Fox and David Funken. 


 
 
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.